Psychedelic Therapy – mechanisms, promises and challenges

As evidence grows for psychedelic therapy across conditions such as depression, addiction and disordered eating, a new question emerges: how do we responsibly integrate these treatments into existing healthcare frameworks?

In this talk, Dr David Erritzoe will begin with an overview of the field – from psychological and neurobiological role of psychedelics as catalysts of flexibility in “stuck” brain networks, to key findings from recent clinical trials. He will then turn to the practical realists of implementation, exploring what healthcare systems can do now to prepare for the coming wave of psychedelic therapies. Drawing on the example of ketamine service plots, David will illustrate how collaboration between public health systems and emerging treatments could offer a balanced and scalable route forward – expanding access while building the evidence base within existing care structures.

Organiser email: [email protected]